



FORM PTO-1449

PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
	FIRST NAMED INVENTOR Upasani <i>et al.</i>	
	FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA1	3,748,331	06/24/1973	Cooke <i>et al.</i>			05/06/1971
AB1	3,963,717	06/15/1976	Cooke <i>et al.</i>			03/10/1975
AC1	5,284,957	02/08/1994	Huff			09/03/1992
AD1	5,514,680	05/07/1996	Weber <i>et al.</i>			11/05/1993
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL1	WO 94/13275	06/23/1993 4	WIPO			Yes
AM1						No
AN1						Yes
AO1						No
AP1						Yes
						No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Anderson, B.A. <i>et al.</i> , "Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164," <i>J. Am. Chem. Soc.</i> 117:12358-12359, American Chemical Society (1995)
AS	1	Buchan, A.M. <i>et al.</i> , "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia," <i>Neuroreport</i> 2:473-476, Lippincott, Williams & Wilkins (1991)
AT	1	Buchan, A.M. <i>et al.</i> , "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" <i>Stroke Suppl. 1</i> 24:I-148-I-154, Lippincott, Williams & Wilkins (1993)

EXAMINER /Cecilia Jaisle/	DATE CONSIDERED 08/02/2008
---------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.